Q4 Earnings Estimate for KALV Issued By Leerink Partnrs

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) – Stock analysts at Leerink Partnrs issued their Q4 2025 EPS estimates for KalVista Pharmaceuticals in a research note issued to investors on Tuesday, March 25th. Leerink Partnrs analyst J. Schwartz forecasts that the specialty pharmaceutical company will post earnings of ($0.77) per share for the quarter. The consensus estimate for KalVista Pharmaceuticals’ current full-year earnings is ($3.56) per share. Leerink Partnrs also issued estimates for KalVista Pharmaceuticals’ Q1 2026 earnings at ($0.72) EPS, Q2 2026 earnings at ($0.60) EPS, Q3 2026 earnings at ($0.53) EPS, Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($2.41) EPS and FY2027 earnings at ($1.27) EPS.

A number of other equities research analysts have also recently weighed in on KALV. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a research note on Friday, March 14th. Jones Trading reaffirmed a “buy” rating and issued a $30.00 target price on shares of KalVista Pharmaceuticals in a research report on Wednesday. JMP Securities began coverage on shares of KalVista Pharmaceuticals in a research report on Friday, January 31st. They set an “outperform” rating and a $19.00 price target on the stock. TD Cowen assumed coverage on shares of KalVista Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating and a $30.00 price objective for the company. Finally, Bank of America assumed coverage on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 18th. They set a “buy” rating and a $22.00 target price on the stock. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $24.83.

KalVista Pharmaceuticals Stock Down 3.3 %

Shares of NASDAQ KALV opened at $11.93 on Friday. The business’s 50 day moving average is $10.56 and its two-hundred day moving average is $10.26. KalVista Pharmaceuticals has a 52-week low of $7.30 and a 52-week high of $15.50. The firm has a market cap of $593.11 million, a price-to-earnings ratio of -3.28 and a beta of 0.76.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC raised its position in shares of KalVista Pharmaceuticals by 10.0% in the fourth quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company’s stock valued at $123,000 after buying an additional 1,319 shares during the last quarter. HighVista Strategies LLC grew its stake in KalVista Pharmaceuticals by 4.5% in the 3rd quarter. HighVista Strategies LLC now owns 33,305 shares of the specialty pharmaceutical company’s stock worth $386,000 after acquiring an additional 1,432 shares during the period. Legal & General Group Plc grew its stake in KalVista Pharmaceuticals by 22.5% in the 4th quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company’s stock worth $69,000 after acquiring an additional 1,494 shares during the period. JPMorgan Chase & Co. raised its holdings in KalVista Pharmaceuticals by 8.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 22,610 shares of the specialty pharmaceutical company’s stock valued at $262,000 after acquiring an additional 1,670 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of KalVista Pharmaceuticals by 24.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock worth $87,000 after purchasing an additional 2,043 shares during the period.

Insider Buying and Selling

In other news, insider Paul K. Audhya sold 3,125 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $9.82, for a total value of $30,687.50. Following the sale, the insider now directly owns 100,334 shares in the company, valued at $985,279.88. This represents a 3.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Venrock Healthcare Capital Par acquired 100,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 12th. The shares were bought at an average cost of $9.23 per share, for a total transaction of $923,000.00. Following the purchase, the insider now owns 5,217,285 shares of the company’s stock, valued at approximately $48,155,540.55. The trade was a 1.95 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 236,055 shares of company stock worth $2,162,146 and have sold 17,292 shares worth $184,625. Insiders own 10.50% of the company’s stock.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).